share_log

ASLAN Says 'The Eblasakimab 400mg Q4W Dosing Arm Did Not Meet the Primary or Secondary Endpoints With Statistical Significance'

ASLAN Says 'The Eblasakimab 400mg Q4W Dosing Arm Did Not Meet the Primary or Secondary Endpoints With Statistical Significance'

ASLAN 說 “Eblasakimab 400mg Q4W 給藥組沒有達到具有統計學意義的主要或次要終點”
Benzinga ·  2023/07/06 07:59

ASLAN Says 'The eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance'

ASLAN 說 “eblasakimab 400mg Q4W 給藥組沒有達到具有統計學意義的主要或次要終點”

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論